Drugs / KSVCBD injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07592754 | May 2026 → Dec 2028 expected | neuromyelitis optica spectrum disorder with anti-AQP4 antibodies | Chinese PLA General Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KSVCBD injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07592754 ↗ |
| Modality | Cell therapy | “KSVCBD injection is a CD19/BCMA-targeted in vivo-edited CAR-T cell injection.” NCT07592754 ↗ |